Stati Uniti - Ingliż - NLM (National Library of Medicine)

apotex corp. - atropine sulfate (unii: 03j5ze7ka5) (atropine - unii:7c0697dr9i) - atropine sulfate ophthalmic solution, 1% is indicated for: atropine sulfate ophthalmic solution should not be used in anyone who has demonstrated a previous hypersensitivity or known allergic reaction to any ingredient of the formulation because it may recur. pregnancy category c: there are no adequate and well-controlled studies of atropine sulfate in pregnant women. animal development and reproduction studies have not been conducted with atropine sulfate. since it is not known whether topically administered atropine sulfate can cause fetal harm, atropine sulfate ophthalmic solution, 1% should only be used during pregnancy if the potential benefit justifies the potential risk to the fetus. traces of atropine have been found in human milk following administration of atropine solution for injection. because some systemic absorption occurs from topical administration, caution should be exercised when atropine sulfate ophthalmic solution, 1% is administered to a nursing woman. due to the potential for systemic absorption of atropine sulfate ophthalmic solution, the use of atropine sulfate ophthalmic solution, 1% in children under the age of 3 months is not recommended and the use in children under 3 years of age should be limited to no more than one drop per eye per day. no overall differences in safety and effectiveness have been observed between elderly and younger adult patients.

Stati Uniti - Ingliż - NLM (National Library of Medicine)

akorn - atropine sulfate (unii: 03j5ze7ka5) (atropine - unii:7c0697dr9i) - atropine sulfate ophthalmic solution, usp 1% is indicated for: atropine sulfate ophthalmic solution should not be used in anyone who has demonstrated a previous hypersensitivity or known allergic reaction to any ingredient of the formulation because it may recur. pregnancy category c: there are no adequate and well-controlled studies of atropine sulfate in pregnant women. animal development and reproduction studies have not been conducted with atropine sulfate. since it is not known whether topically administered atropine sulfate can cause fetal harm, atropine sulfate ophthalmic solution, usp 1% should only be used during pregnancy if the potential benefit justifies the potential risk to the fetus. traces of atropine have been found in human milk following administration of atropine solution for injection. because some systemic absorption occurs from topical administration, caution should be exercised when atropine sulfate ophthalmic solution, usp 1% is administered to a nursing woman. due to the potential fo

Stati Uniti - Ingliż - NLM (National Library of Medicine)

medefil, inc. - atropine sulfate (unii: 03j5ze7ka5) (atropine - unii:7c0697dr9i) - atropine sulfate injection, usp, is indicated for temporary blockade of severe or life threatening muscarinic effects, e.g., as an antisialagogue, an antivagal agent, an antidote for organophosphorus or muscarinic mushroom poisoning, and to treat bradyasystolic cardiac arrest. these highlights do not include all the information needed to use atropine sulfate injection safely and effectively. see full prescribing information for atropine sulfate injection. atropine sulfate injection, for intravenous use initial u.s. approval: 1960 none. 8.1 pregnancy animal reproduction studies have not been conducted with atropine. it also is not known whether atropine can cause fetal harm when given to a pregnant woman or can affect reproduction capacity. 8.3 nursing mothers trace amounts of atropine was found in breast milk. the clinical impact of this is not known. 8.4 pediatric use recommendations for use in pediatric patients are not based on clinical trials. 8.5 geriatric use an evaluation of current literature revealed

Stati Uniti - Ingliż - NLM (National Library of Medicine)

alcon laboratories, inc. - atropine sulfate (unii: 03j5ze7ka5) (atropine - unii:7c0697dr9i) - atropine sulfate 10 mg in 1 ml - isopto® atropine 1% is indicated for: atropine sulfate ophthalmic solution should not be used in anyone who has demonstrated a previous hypersensitivity or known allergic reaction to any ingredient of the formulation because it may recur. risk summary there are no adequate and well-controlled studies with isopto® atropine 1% administration in pregnant women to inform a drug-associated risk. adequate animal development and reproduction studies have not been conducted with atropine sulfate. in humans, 1% atropine sulfate is systemically bioavailable following topical ocular administration [see clinical pharmacology (12.3)] . isopto® atropine 1% should only be used during pregnancy if the potential benefit justifies the potential risk to the fetus. there is no information to inform risk regarding the presence of atropine in human milk following ocular administration of isopto® atropine 1% to the mother. the effects on breastfed infants and the effects on milk production are also unknown.  the developmental a

Stati Uniti - Ingliż - NLM (National Library of Medicine)

hikma pharmaceuticals usa inc. - atropine sulfate (unii: 03j5ze7ka5) (atropine - unii:7c0697dr9i) - atropine sulfate 0.4 mg in 1 ml - atropine sulfate is given parenterally as a preanesthetic medication to decrease salivation and bronchial secretions. it is useful in pylorospasm and other spastic conditions of the gastrointestinal tract. for ureteral and biliary colic, atropine sulfate given with morphine may be indicated. atropine sulfate is indicated for relaxation of the upper gastrointestinal tract and colon during hypotonic radiography. atropine is used as an antidote for pilocarpine, physostigmine, isoflurophate, choline esters, certain species of aminata and in poisoning by the organic phosphate cholinesterase inhibitors found in certain insecticides and by chemical warfare “nerve gases”. large doses relieve the muscarine-like symptoms and some of the central nervous system manifestations. conditions at which inhibition of postganglionic cholinergic nerves are undesirable, such as glaucoma and tachycardia. also contraindicated in asthma, because the parenteral dose which might relieve asthma would have an excessive drying effect upo

Stati Uniti - Ingliż - NLM (National Library of Medicine)

medical purchasing solutions, llc - atropine sulfate (unii: 03j5ze7ka5) (atropine - unii:7c0697dr9i) - atropine sulfate 0.1 mg in 1 ml - atropine sulfate injection, usp, may be given parenterally as a pre-anesthetic medication in surgical patients to reduce salivation and bronchial secretions. it may also be used to suppress vagal activity associated with the use of halogenated hydrocarbons during inhalation anesthesia and reflex excitation arising from mechanical stimulation during surgery. the antispasmodic action of atropine is useful in pylorospasm and other spastic conditions of the gastrointestinal tract. for ureteral and biliary colic, atropine concomitantly with morphine may be indicated. atropine relaxes the upper gi tract and colon during hypotonic radiography. in poisoning by the organic phosphate cholinesterase inhibitors found in certain insecticides and by chemical warfare nerve gases, large doses of atropine relieve the muscarine-like symptoms and some of the central nervous system manifestations. it is also used as an antidote for mushroom poisoning due to muscarine in certain species such as amanita muscaria . atr

Unjoni Ewropea - Ingliż - EMA (European Medicines Agency)

biopartners gmbh - somatropin - growth - pituitary and hypothalamic hormones and analogues, somatropin and somatropin agonists - somatropin biopartners is indicated for the replacement therapy of endogenous growth hormone in adults with childhood- or adult-onset growth-hormone deficiency (ghd).adult-onset: patients with ghd in adulthood are defined as patients with known hypothalamic-pituitary pathology and at least one additional known deficiency of a pituitary hormone excluding prolactin. these patients should undergo a single dynamic test in order to diagnose or exclude a ghd.childhood-onset: in patients with childhood-onset isolated ghd (no evidence of hypothalamic-pituitary disease or cranial irradiation), two dynamic tests should be performed after completion of growth, except for those having low insulin-like-growth-factor-i (igf-i) concentrations (< -2 standard-deviation score (sds)), who may be considered for one test. the cut-off point of the dynamic test should be strict.

Stati Uniti - Ingliż - NLM (National Library of Medicine)

rafa laboratories, ltd. - atropine (unii: 7c0697dr9i) (atropine - unii:7c0697dr9i) - atropine 1 mg in 0.7 ml - atropine is indicated for the treatment of poisoning by susceptible organophosphorus nerve agents having anticholinesterase activity as well as organophosphorus or carbamate insecticides in adults and pediatric patients weighing more than 41 kg (90 pounds). none. pregnancy risk summary atropine readily crosses the placental barrier and enters fetal circulation. there are no adequate data on the developmental risk associated with the use of atropine in pregnant women. adequate animal reproduction studies have not been conducted with atropine. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. the background risk of major birth defects and miscarriage for the indicated population is unknown. lactation risk summary atropine has been reported to be excreted in human milk. there are no data on the effects of atropine on the breastfed infant or the effects of the drug on milk production.

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - atropine sulfate monohydrate, quantity: 600 microgram/ml; sodium hydroxide - injection, solution - excipient ingredients: water for injections; sodium chloride; sulfuric acid - indications as at 30 september 2003:surgery : atropine may be given as a pre-anaesthetic medication to inhibit excessive salivary and bronchial secretions and to diminish the risk of vagal inhibition of the heart. the use of atropine as an antisialogogue is rarely necessary since the introduction of halothane and similar anaesthetics in place of ether anaesthesia. after surgery atropine may also be administered concurrently with anticholinesterase agents (e.g. neostigmine, physostigmine) when used to terminate curarisation to counteract the adverse muscarinic effects of these drugs. cardiopulmonary resuscitation : atropine may be used during cardiopulmonary resuscitation to treat sinus bradycardia and associated hypotension, and increased ventricular irritability. anticholinesterase poisoning : atropine juno is also used in the treatment of sinus bradycardia induced by organophosphate pesticides, amanita muscaria mushrooms or other compounds with anticholinesterase activity. a cholinesterase reactivator, e.g. pralidoxime iodide, may be given concurrently.

Stati Uniti - Ingliż - NLM (National Library of Medicine)

bausch & lomb incorporated - atropine sulfate (unii: 03j5ze7ka5) (atropine - unii:7c0697dr9i) - atropine sulfate 10 mg in 1 g - for mydriasis and/or cycloplegia. for cycloplegic refraction, for pupillary dilation desired in inflammatory conditions of the iris and uveal tract. this product should not be used in patients with primary glaucoma or a predisposition to narrow anterior chamber angle glaucoma. this product should not be used in pediatric patients who have previously had a severe systemic reaction to atropine. this product should not be used in those persons showing hypersensitivity to any component of this preparation.